A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) Meeting Abstract


Authors: Gaspar, N.; Campbell-Hewson, Q.; Bielack, S. S.; Campbell, M.; Bautista, F.; Meazza, C.; Janeway, K.; Dela Cruz, F. S.; Whittle, S. B.; Morgenstern, D. A.; Dutta, L.; McKenzie, J.; O'Hara, K.; Huang, J.; Okpara, C. E.; Bidadi, B.; Koh, K. N.; Morland, B.
Abstract Title: A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Meeting Title: ESMO Virtual Congress 2020
Journal Title: Annals of Oncology
Volume: 31
Issue: Suppl. 4
Meeting Dates: 2020 Sep 19-21/Oct 16-18
Meeting Location: Virtual
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2020-09-01
Start Page: S990
End Page: S991
Language: English
ACCESSION: WOS:000573469102254
DOI: 10.1016/j.annonc.2020.08.1893
PROVIDER: wos
Notes: Meeting Abstract: 1668TiP -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors